Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Rhea-AI Summary

Cassava Sciences, Inc. (Nasdaq: SAVA) will announce its financial results for Q2 2021 on August 3, 2021, before market opening. A conference call led by President & CEO Remi Barbier and CFO Eric Schoen will follow at 9 a.m. ET to discuss the results and growth strategy. Alzheimer's disease affects nearly 50 million people globally, with costs exceeding $1 trillion annually. The company is committed to developing innovative solutions for neurodegenerative conditions. Investors can access the event via the company’s website.

Positive

• Company focuses on addressing Alzheimer's disease, a major global health issue.
• Expected conference call may provide insights into growth strategies and future guidance.

Negative

• None.

- Call-in on Tuesday, August 3rd at 9 a.m. ET -

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.

Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company’s growth strategy.

The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021. Please dial in 15 minutes in advance to ensure a timely connection to the call.

Conference call detail are as follows:
Toll Free:		1-888-254-3590
Toll/International:		1-323-794-2575

After the live call, the event will be archived on the ‘Investors’ page of the Company’s website: https://www.CassavaSciences.com.

Live Event Click to Join Link (for participant entry):

https://event.mymeetingroom.com/Public/ClickToJoin/ZW5jPXZYWEV4Yks0aWhyTWp1ZnBWOTF1Zk5zaHl1NW5jVGVodEtGUTJ0WFZJNjREdWd1VUZYY0drdz09
	Participants can use Guest dial-in #s above and be answered by an operator OR click the Click to Join link for instant telephone access to the event
	Click to Join link will be made active 15 minutes prior to scheduled start time.

About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.¹ The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.

For More Information Contact:
Eric Schoen, Chief Financial Officer
eschoen@CassavaSciences.com
(512) 501-2450

For information regarding risks related to our business, investors please consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.

¹ Alzheimer's Disease International, Dementia Statistics, available on-line.

FAQ

When will Cassava Sciences release its Q2 2021 earnings?

Cassava Sciences will release its Q2 2021 earnings on August 3, 2021.

What time is the Cassava Sciences conference call scheduled?

The conference call is scheduled for 9 a.m. ET on August 3, 2021.

How can investors access the Cassava Sciences conference call?

Investors can access the conference call by dialing in using the provided toll-free or international numbers.

What are the major health concerns related to Alzheimer's disease?

Alzheimer's disease currently affects approximately 50 million people worldwide, with projections to rise to 150 million by 2050.

What is the focus of Cassava Sciences?

Cassava Sciences focuses on developing innovations for chronic, neurodegenerative conditions, particularly Alzheimer's disease.